Click here to get full coverage on Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress  Yahoo Finance

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance

Click here to get full coverage on Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock - Investing.com

Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock  Investing.com

Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock - Investing.com

Click here to get full coverage on Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires?  simplywall.st

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st

Click here to get full coverage on Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan

Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k  Stock Titan

Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan

Click here to get full coverage on Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - Sahm

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires?  Sahm

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - Sahm

Click here to get full coverage on Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock - MarketBeat

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock  MarketBeat

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock - MarketBeat

Click here to get full coverage on $MLYS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

$MLYS stock is up 13% today. Here's what we see in our data.  Quiver Quantitative

$MLYS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus

Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS)  GuruFocus

Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus

Click here to get full coverage on Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com

Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock  Investing.com

Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com

Click here to get full coverage on Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan

Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan  Stock Titan

Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Yahoo Finance

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension  Yahoo Finance

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Yahoo Finance

Click here to get full coverage on Investors Purchase High Volume of Mineralys Therapeutics Put Options (NASDAQ:MLYS) - MarketBeat

Investors Purchase High Volume of Mineralys Therapeutics Put Options (NASDAQ:MLYS)  MarketBeat

Investors Purchase High Volume of Mineralys Therapeutics Put Options (NASDAQ:MLYS) - MarketBeat

Click here to get full coverage on Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares  Stock Titan

Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4% - What's Next? - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4% - What's Next?  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4% - What's Next? - MarketBeat

Click here to get full coverage on MLYS Jun 2026 17.500 put (MLYS260618P00017500) Interactive Stock Chart - Yahoo! Finance Canada

MLYS Jun 2026 17.500 put (MLYS260618P00017500) Interactive Stock Chart  Yahoo! Finance Canada

MLYS Jun 2026 17.500 put (MLYS260618P00017500) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan

Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares  Stock Titan

Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan

Click here to get full coverage on SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat

SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS  MarketBeat

SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Click here to get full coverage on Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?  Yahoo Finance

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance

Click here to get full coverage on RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan

RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares  Stock Titan

RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan

Click here to get full coverage on Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance

Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback  Yahoo Finance

Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance

Click here to get full coverage on (MLYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

(MLYS) as a Liquidity Pulse for Institutional Tactics  Stock Traders Daily

(MLYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Click here to get full coverage on MLYS Apr 2026 40.000 call (MLYS260417C00040000) stock price, news, quote and history - Yahoo Finance UK

MLYS Apr 2026 40.000 call (MLYS260417C00040000) stock price, news, quote and history  Yahoo Finance UK

MLYS Apr 2026 40.000 call (MLYS260417C00040000) stock price, news, quote and history - Yahoo Finance UK

Click here to get full coverage on Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed - simplywall.st

Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed  simplywall.st

Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA Acceptance - What's Changed - simplywall.st

Click here to get full coverage on MLYS Apr 2026 20.000 put (MLYS260417P00020000) Stock Historical Prices & Data - Yahoo! Finance Canada

MLYS Apr 2026 20.000 put (MLYS260417P00020000) Stock Historical Prices & Data  Yahoo! Finance Canada

MLYS Apr 2026 20.000 put (MLYS260417P00020000) Stock Historical Prices & Data - Yahoo! Finance Canada

Click here to get full coverage on Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan

Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026  Stock Titan

Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Yahoo Finance

Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones  Yahoo Finance

Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Yahoo Finance

Click here to get full coverage on Mineralys spikes as blood pressure drug undergoes FDA review - Seeking Alpha

Mineralys spikes as blood pressure drug undergoes FDA review  Seeking Alpha

Mineralys spikes as blood pressure drug undergoes FDA review - Seeking Alpha

Click here to get full coverage on New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan

New Mineralys hire gets stock options and RSUs vesting over four years  Stock Titan

New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan

Click here to get full coverage on Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan

Mineralys brings in veteran biotech lawyer as it advances lorundrostat  Stock Titan

Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan

Click here to get full coverage on Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis

Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint  Trefis

Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis

Click here to get full coverage on MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings - Quiver Quantitative

MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings  Quiver Quantitative

MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan

Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions  Stock Titan

Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan

Click here to get full coverage on Mineralys Therapeutics (MLYS) Valuation After FDA Acceptance Of Lorundrostat NDA In Hypertension - simplywall.st

Mineralys Therapeutics (MLYS) Valuation After FDA Acceptance Of Lorundrostat NDA In Hypertension  simplywall.st

Mineralys Therapeutics (MLYS) Valuation After FDA Acceptance Of Lorundrostat NDA In Hypertension - simplywall.st

Click here to get full coverage on David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan

David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026  Stock Titan

David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan

Click here to get full coverage on HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS  MarketBeat

HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Click here to get full coverage on Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Biotech Mineralys offers 4-year stock awards to new hires  Stock Titan

Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan

Click here to get full coverage on Blood pressure drug wins FDA review as apnea study shows no gain - Stock Titan

Blood pressure drug wins FDA review as apnea study shows no gain  Stock Titan

Blood pressure drug wins FDA review as apnea study shows no gain - Stock Titan

Click here to get full coverage on Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 By Investing.com - za.investing.com

Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 By Investing.com  za.investing.com

Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 By Investing.com - za.investing.com

Click here to get full coverage on Mineralys Therapeutics(MLYS.US) Director Buys US$8.76 Million in Common Stock - 富途牛牛

Mineralys Therapeutics(MLYS.US) Director Buys US$8.76 Million in Common Stock  富途牛牛

Mineralys Therapeutics(MLYS.US) Director Buys US$8.76 Million in Common Stock - 富途牛牛

Click here to get full coverage on What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? - Yahoo Finance

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?  Yahoo Finance

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Click here to get full coverage on Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak  Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan

Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares  Stock Titan

Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan

Click here to get full coverage on Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans - Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans  Yahoo Finance

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans - Yahoo Finance

Click here to get full coverage on Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan

Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan  Stock Titan

Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on Hypertension drug developer Mineralys sets March 12 call on 2025 results - Stock Titan

Hypertension drug developer Mineralys sets March 12 call on 2025 results  Stock Titan

Hypertension drug developer Mineralys sets March 12 call on 2025 results - Stock Titan

Click here to get full coverage on MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS  TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Click here to get full coverage on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages  MarketBeat

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions - Stock Titan

David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions  Stock Titan

David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions - Stock Titan

Click here to get full coverage on Mineralys Therapeutics MLYS CMO sells shares worth $542,973 - Investing.com

Mineralys Therapeutics MLYS CMO sells shares worth $542,973  Investing.com

Mineralys Therapeutics MLYS CMO sells shares worth $542,973 - Investing.com

Click here to get full coverage on Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News - Quiver Quantitative

Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News  Quiver Quantitative

Insider Sale: Chief Medical Officer of $MLYS Sells 70,037 Shares | MLYS Stock News - Quiver Quantitative

Click here to get full coverage on New blood pressure drug shows promise for hard-to-treat patients - Stock Titan

New blood pressure drug shows promise for hard-to-treat patients  Stock Titan

New blood pressure drug shows promise for hard-to-treat patients - Stock Titan

Click here to get full coverage on David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat

David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock  MarketBeat

David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat

Click here to get full coverage on Insider Sale: Chief Executive Officer of $MLYS Sells 7,117 Shares - Quiver Quantitative

Insider Sale: Chief Executive Officer of $MLYS Sells 7,117 Shares  Quiver Quantitative

Insider Sale: Chief Executive Officer of $MLYS Sells 7,117 Shares - Quiver Quantitative

Click here to get full coverage on Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS  MarketBeat

Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Click here to get full coverage on Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)  Seeking Alpha

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha

Click here to get full coverage on David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat

David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock  MarketBeat

David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat

Click here to get full coverage on David Rodman (NASDAQ: MLYS) sells 192,715 shares; multiple trades listed - Stock Titan

David Rodman (NASDAQ: MLYS) sells 192,715 shares; multiple trades listed  Stock Titan

David Rodman (NASDAQ: MLYS) sells 192,715 shares; multiple trades listed - Stock Titan

Click here to get full coverage on MLYS Apr 2026 20.000 put (MLYS260417P00020000) Interactive Stock Chart - Yahoo! Finance Canada

MLYS Apr 2026 20.000 put (MLYS260417P00020000) Interactive Stock Chart  Yahoo! Finance Canada

MLYS Apr 2026 20.000 put (MLYS260417P00020000) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares  MarketBeat

Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat

Click here to get full coverage on Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com

Rodman sells Mineralys (MLYS) shares for $13,353  Investing.com

Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com

Click here to get full coverage on Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com

Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock  Investing.com

Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com

Click here to get full coverage on Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat

Research Analysts Issue Forecasts for MLYS Q1 Earnings  MarketBeat

Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat

Click here to get full coverage on Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS  MarketBeat

Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Click here to get full coverage on Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS)  Seeking Alpha

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha

Click here to get full coverage on Mineralys (MLYS) Jumps More Than 12% During the Day as Market Swings and Chart Patterns Present a Risky Prospect - Bitget

Mineralys (MLYS) Jumps More Than 12% During the Day as Market Swings and Chart Patterns Present a Risky Prospect  Bitget

Mineralys (MLYS) Jumps More Than 12% During the Day as Market Swings and Chart Patterns Present a Risky Prospect - Bitget

Click here to get full coverage on Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS - FinancialContent

Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS  FinancialContent

MLYS

Price Chart

Key Statistics

Technicals

About MLYS

Latest News

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance

Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock - Investing.com

Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st

Advanced Charts

Top Gainers

Top Losers